FindTrial
Sign In

2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests

2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040764
Enrollment
Unknown
Registered
2020-12-09
Start date
2018-03-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Gold Standard:The diagnostic criteria of MM can be summarized into three aspects: ? The abnormal proliferation of plasma fine cells in the bone marrow must be emphasized not only for the increase in t
Index test:Blood&#32
routine,&#32
biochemical&#32
index,&#32
bone&#32
marrow&#32
report,&#32
serum&#32
protein&#32
electrophoresis,&#32
immunoelectrophoresis,&#32
light&#32
chain&#32
quantitative&#32
method

Sponsors

Changzheng Hospital, Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma need blood transfusion.

Exclusion criteria

Exclusion criteria: Patients with multiple myeloma do not need blood transfusion.

Design outcomes

Primary

MeasureTime frame
Cross matching;—

Countries

China

Contacts

Public ContactXiaofeng Tang

Changzheng Hospital, Naval Medical University,

jack_tangxf@163.com+86 021 81886094

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026